RxDoctor Payments Data

Chris Marino, MD

Neurology · Fort Myers, FLNPI 1417950635

Payments from drug & device makers

$11,768in general payments, 2019–2025

Across 620 payments — averaging $18.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$887
  • Acadia Pharmaceuticals Inc$576
  • Lundbeck LLC$507
  • Novartis$506
  • Amgen$484
  • plus $7K from 54 others

What the payments were for

  • Speaking & faculty fees$360%
  • Food & beverage$11,67299%
  • Education$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)108$1,802
UCB, Inc.33$887
Acadia Pharmaceuticals Inc39$576
Lundbeck LLC21$507
Novartis26$506
Amgen(2 entities)27$484
GE HealthCare23$414
Sanofi17$412
AstraZeneca17$411
Genentech USA, Inc.23$400
Pfizer24$396
EMD Serono, Inc.16$345
Argenx US, Inc.13$323
Eisai Inc.13$302
Bristol Myers Squibb12$247
Teva Pharmaceuticals USA, Inc.13$238
Neurocrine Biosciences, Inc.8$210
Lilly USA, LLC13$208
Amneal Pharmaceuticals LLC10$195
Biohaven Pharmaceuticals, Inc.13$186
SK Life Science, Inc.6$167
Biogen8$155
Supernus Pharmaceuticals, Inc.16$149
Tanabe Pharma America, Inc.5$138
MDD US Operations, LLC6$133
Catalyst Pharmaceuticals, Inc.6$126
Sunovion Pharmaceuticals Inc.9$125
Octapharma USA, Inc.7$124
Biohaven Pharmaceutical Holding Company Ltd.9$123
Merz Pharmaceuticals, LLC5$120
Avion Pharmaceuticals6$103
Alnylam Pharmaceuticals Inc.4$97
Grifols USA, LLC5$96
Otsuka America Pharmaceutical, Inc.4$87
Takeda Pharmaceuticals U.S.A., Inc.3$78
Sanofi-aventis U.S. LLC4$73
E.r. Squibb & Sons, L.L.C.4$69
Sumitomo Pharma America, Inc.3$62
Ipsen Biopharmaceuticals, Inc3$61
Avanir Pharmaceuticals, Inc.4$53
Jazz Pharmaceuticals Inc.2$47
TG Therapeutics, Inc.2$41
Greenwich Biosciences, Inc.3$40
Adamas Pharmaceuticals, Inc.2$37
Acorda Therapeutics, Inc2$36
Kyowa Kirin, Inc.2$35
Impel Pharmaceuticals Inc.2$33
Aprecia Pharmaceuticals, LLC2$32
Insightec,inc2$28
Corium, LLC1$27
Johnson & Johnson2$26
Upsher-smith Laboratories LLC2$26
Revance Therapeutics, Inc.1$22
Almatica Pharma LLC1$22
Medtronic1$20
CSL Behring1$20
Merz North America, Inc.1$20
Zyla Life Sciences, Inc.1$15
Mylan Specialty L.p.1$15
Portola Pharmaceuticals, LLC1$14

How this compares

$11,768 in reported general payments places this provider in the 65th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$1,126,360
Medicare patients
920
Services billed
39,767

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SolirisEculizumab18$993,752
FirdapseAmifampridine Phosphate15$806,680
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5022$243,565
AustedoDeutetrabenazine22$215,475
Gamunex-CImmune Globul G/Gly/Iga Avg 4614$196,653
GammakedImmune Globul G/Gly/Iga Avg 4612$195,021
CopaxoneGlatiramer Acetate25$143,460
Vigabatrin13$130,144
Aimovig AutoinjectorErenumab-Aooe25$23,801
Nurtec OdtRimegepant Sulfate11$16,746
Carbidopa-LevodopaCarbidopa/Levodopa193$6,842
Levetiracetam123$4,672
Memantine Hcl138$4,203
Carbamazepine ErCarbamazepine11$3,401
Oxcarbazepine19$3,235

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaSoliris$411$993,75218 claims
Catalyst Pharmaceuticals, Inc.Firdapse$126$806,68015 claims
Teva Pharmaceuticals USA, Inc.Austedo, Copaxone$238$358,93547 claims
CSL BehringPrivigen$20$243,56522 claims
Grifols USA, LLCGamunex-C$96$196,65314 claims
PfizerNurtec Odt$396$16,74611 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$195$2,20129 claims
Upsher-smith Laboratories LLCTopiramate$26$27734 claims
Almatica Pharma LLCSertraline Hcl$22$8416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,434 neurology providers in Florida.

Other neurology in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →